Effect of tacrolimus on activity and expression of Pgp and ABCA5 proteins in hematoencephalic barrier cells

Quezada C., Garrido W, González-Oyarzún M, Rauch M.C., Salas M, San Martín R., Claude A., Yañez A., Slebe J.C. and Cárcamo J.G.

Keywords: Tacrolimus, MDR


Tacrolimus is an agent used in clinical immunosuppressive drug therapies. A wide spectrum of adverse effects has been reported in association with this immunosuppressor, including neurotoxic effect. The upper limit of therapeutic blood concentrations of tacrolimus has been described as 30 ng/ml in immunosuppressed patients. We investigated the effect of this therapeutic dose of tacrolimus on the expression and activity of the multidrug resistance protein 1 (MDR1 or Pgp, P-glycoprotein) and ATP-binding cassette transporters A5 (ABCA5) in human brain microvascular endothelial cells (HBMEC), derived from Blood-Brain Barrier (BBB) endothelium, these being the most predominantly expressed transcripts in these cells. The expression and activity of MDR1 transporter decreased with 30 ng/ml tacrolimus. The cell viability was not changed with the therapeutic dose used. By contrast, ABCA5 transcripts, of unknown role as yet, increased their expression at this concentration. We propose that the secondary cytotoxic effects of this immunosuppressor on CSN, besides the functional blockade related to multidrug resistance proteins, such as MDR1, and probably ABCA5, could be linked to variations in the expression levels of these proteins at the BBB.

Más información

Título de la Revista: Biological and Pharmaceutical Bulletin
Volumen: 31
Fecha de publicación: 2008
Página de inicio: 1911
Página final: 1916
Idioma: English
Financiamiento/Sponsor: 11080226
Notas: ISI